Home
    Disclaimer
    ← Back to U-47700
    U-47700 molecular structure

    U-47700 Stats & Data

    Depressant Research-chemical Opioid
    U4 Pink Pinky Pink heroin u47700
    NPS DataHub
    MW329.27
    FormulaC16H22Cl2N2O
    CAS121348-98-9
    IUPAC3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-methylbenzamide
    SMILESCN(C)C1CCCCC1N(C)C(=O)c1ccc(Cl)c(Cl)c1
    InChIKeyJGPNMZWFVRQNGU-LSDHHAIUSA-N
    Opioids; 2020/4. Von N-(2-Aminocyclohexyl)amid abgeleitete Verbindungen; 2021/4. Von N-(2-Aminocyclohexyl)amid abgeleitete Verbindungen; 2022/4. Von N-(2-Aminocyclohexyl)amid abgeleitete Verbindungen
    Chemical Class Opioid
    Psychoactive Class Depressant

    Pharmacology

    DrugBank

    Mechanism of Action

    /ALTERNATIVE and IN VITRO TESTS/ U-47700 /was evaluated/ for its in vitro binding activity using guinea pig brain at the mu opioid receptor (MOR) and the kappa opioid receptor (KOR). U-47700 had high affinity at the MOR and bound with a KD of 5.3 nM and weakly at the KOR with a KD of 910 nM resulting in a >171x preference for the MOR relative to the KOR. (14) Subsequently these researchers reported U-47700 receptor affinities (IC50s) of 9 and 300 nM, respectively, for the MOR and KORs.

    Metabolism

    Recently, the number of adverse events, including death, involving novel opioids has continued to increase, providing additional and sustained challenges for forensic and medical communities. Identification of emerging novel opioids can be challenging, compounded by detection windows and unknown metabolic profiles. In this study, human liver microsomes were used for the generation of in vitro metabolic profiles of U-47700 and U-49900. Generated metabolites were analyzed via a SCIEX TripleTOF 560

    Receptor Profile

    Receptor Actions

    Agonists
    μ-opioid receptor agonist (full)
    κ-opioid receptor agonist (weak)
    δ-opioid receptor agonist (very weak)

    Effect Profile

    Curated + 9 Reports
    Opioid 8.0

    Strong euphoria and pain relief with mild sedation and itching/nausea

    Euphoria / Warmth×3
    10
    Analgesia×2
    8
    Sedation / Relaxation×1
    4
    Itching / Nausea×1
    4
    Based on reports from:
    Erowid Experience Reports PsychonautWiki U-47700

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1d Half tolerance 21d Baseline ~35d

    Experience Report Analysis

    Erowid
    9 Reports
    2014–2017 Date Range
    9 With Age Data
    4 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 9 experience reports (9 Erowid)

    9 Reports
    4 Effects Detected
    3 Positive
    0 Adverse
    1 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 3

    Sedation 44.4% 70%
    Euphoria 44.4% 70%
    Anxiety Suppression 33.3% 70%

    Adverse Effects 0

    Form / Preparation

    Most common forms and preparations reported

    Read full reports on Erowid →

    Legal Status

    Country Status Notes
    Austria illegal Controlled under SMG (Suchtmittelgesetz) since June 26, 2019.
    Czech Republic controlled Schedule I controlled substance.
    Sweden illegal Classified as a narcotic substance.
    United Kingdom controlled Class A, Schedule 1 substance.
    United States controlled Schedule I since October 2016. Originally temporarily scheduled; now permanently controlled as a synthetic opioid.
    United States - Florida controlled Emergency scheduled at state level.
    United States - Ohio controlled Emergency scheduled at state level.

    References

    Data Sources

    Cited References

    ← Back to U-47700